Raab Stephen S, Grzybicki Dana Marie, Zarbo Richard J, Jensen Chris, Geyer Stanley J, Janosky Janine E, Meier Frederick A, Vrbin Colleen M, Carter Gloria, Geisinger Kim R
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, and Western Pennsylvania Hospital 15232, USA.
Am J Clin Pathol. 2007 Nov;128(5):817-24. doi: 10.1309/97JHG6GLY69BVF4Y.
We measured the frequency and outcome of cervical cancer prevention failures that occurred in the Papanicolaou (Pap) and colposcopy testing phases involving 1,646,580 Pap tests in 4 American hospital systems between January 1, 1998, and December 31, 2004. We defined a screening failure as a 2-step or greater discordant Pap test result and follow-up biopsy diagnosis. A total of 5,278 failures were detected (0.321% of all Pap tests); 48% and 52% of failures occurred in the Pap test and colposcopy phases, respectively. Missed squamous cancers (1 in 187,786 Pap tests), glandular cancers (1 in 19,426 Pap tests), and high-grade lesions (1 in 6,870 Pap tests) constituted 4.1% of all failures. Unnecessary repeated tests or diagnostic delays occurred in 70.8% and 63.9% of failures involving high- and low-grade lesions, respectively. We conclude that cervical cancer prevention practices are remarkably successful in preventing squamous cancers, although a high frequency of failures results in low-impact negative outcomes.
我们对1998年1月1日至2004年12月31日期间美国4家医院系统中1,646,580次巴氏涂片检查(Pap)和阴道镜检查阶段发生的宫颈癌预防失败的频率和结果进行了测量。我们将筛查失败定义为两步或更高级别的不一致巴氏涂片检查结果及后续活检诊断。共检测到5278例失败(占所有巴氏涂片检查的0.321%);分别有48%和52%的失败发生在巴氏涂片检查和阴道镜检查阶段。漏诊的鳞状细胞癌(每187,786次巴氏涂片检查中有1例)、腺癌(每19,426次巴氏涂片检查中有1例)和高级别病变(每6,870次巴氏涂片检查中有1例)占所有失败的4.1%。在涉及高级别和低级别病变的失败中,分别有70.8%和63.9%发生了不必要的重复检查或诊断延迟。我们得出结论,宫颈癌预防措施在预防鳞状细胞癌方面非常成功,尽管高失败频率导致了影响较小的负面结果。